Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 52 results
Filters: First Letter Of Title is H  [Clear All Filters]
Found 52 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Abu-Raddad LJ, Barnabas RV, Janes H, et al. "Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?" AIDS. 2013;27(6):981-9.
Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE. "Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study." J. Viral Hepat.. 2012;19(11):792-800.
Behler CM, Vittinghoff E, Lin F, et al. "Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects." Clin. Infect. Dis.. 2007;44(10):1375-83.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Kallianpur AR, Gerschenson M, Hulgan T, et al. "Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy." AIDS Res. Hum. Retroviruses. 2018;34(11):942-949.
Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. "Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177." J. Acquir. Immune Defic. Syndr.. 2010;54(4):e7-9.
Sherman KE, Rouster SD, Stanford S, et al. "Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens." J. Infect. Dis.. 2010;201(5):712-9.
Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. "Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment." AIDS. 2013;27(17):2725-34.
Haas DW, Koletar SL, Laughlin L, et al. "Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir." J. Acquir. Immune Defic. Syndr.. 2009;50(3):290-3.
Ngongondo MN, Miyahara S, Hughes MD, et al. "Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial." J. Acquir. Immune Defic. Syndr.. 2018;78(1):54-61.
Celum C, Hong T, Cent A, et al. "Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study." J. Infect. Dis.. 2017;215(6):907-910.
Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ. "Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection." J. Infect. Dis.. 2007;195(9):1270-7.
Healy B, Degruttola V. "Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses." Biostatistics. 2007;8(2):438-52.
Huang Y, Liu D, Wu H. "Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system." Biometrics. 2006;62(2):413-23.
Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.
Cranston RD, Cespedes MS, Paczuski P, et al. "High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298." Sex Transm Dis. 2018;45(4):266-271.
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
J Chang J, Woods M, Lindsay RJ, et al. "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication." J. Infect. Dis.. 2013;208(5):830-8.
Wilkin T, Lee JY, Lensing SY, et al. "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine." HIV Clin Trials. 2013;14(2):75-9.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Shah, iv S, Mildvan D. "HIV and aging." Curr Infect Dis Rep. 2006;8(3):241-7.
Robertson KR, Jiang H, Kumwenda J, et al. "HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings." Clin. Infect. Dis.. 2018.
Yonkers NL, Rodriguez B, Post AB, et al. "HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells." J. Infect. Dis.. 2006;194(3):391-400.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Bronke C, Almeida C-AM, McKinnon E, et al. "HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes." AIDS. 2013;27(6):899-905.
Simpson DM, Kitch D, Evans SR, et al. "HIV neuropathy natural history cohort study: assessment measures and risk factors." Neurology. 2006;66(11):1679-87.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.

Pages